High-dose hydroxyurea with differentiating agents for treating ultra-high-risk acute promyelocytic leukemia in resource-challenged settings

Figures & data

Table 1. Comparison of high-risk APL patients treated with and without high-dose hydroxyurea.

Characteristics	High dose hydroxyurea (N = 15) N (%), median (range)	No High dose hydroxyurea (N = 17) N (%), median (range)	p-value
Age (years)	23 (12–48)	35 (12–56)	0.2
Gender
Males	9 (60%)	8 (47%)	0.4
Females	6 (40%)	9 (53%)
Median WBC (×10^9/L)	81.7 (31.1–188.8)	58.3 (33.4–170.9)	0.3
WBC > 50 (×10^9/L)	11 (73%)	9 (53%)	0.3
WBC > 100 (×10^9/L)	7 (47%)	4 (24%)	0.2
Coagulopathy	8 (53%)	13 (77%)	0.2
Major Bleed	2 (13%)	5 (29%)	0.4
Intracranial Bleed	2 (13%)	3 (18%)	1.0
Differentiation syndrome	5 (33%)	5 (29%)	0.8
Cumulative Hydroxyurea dose (g)	57 (15–112)	13 (5–51)	<0.001
Hydroxyurea duration	7 (2–15)	3 (2–17)	0.3
Packed Red Cell Transfusions	4 (2–8)	4 (2–11)	0.551
Fresh Frozen Plasma Transfusions	3 (0–22)	4 (0–7)	0.737
Cryoprecipitate Transfusions	4 (0–8)	5 (0–9)	0.682
Platelet Transfusions (RDP + SDAP)	9 (5–20)	8 (5–20)	0.313
Days to reversal of Coagulopathy	8 (2–15)	7 (3–10)	0.133
Early mortality (within seven days)	2 (13%)	9 (53%)	0.02
Hepatotoxicity (Grade 3–4)	4 (27%)	1 (6%)	0.1
Days with ANC <0.5×10^9/L	11 (2–18)	9 (2–17)	0.602
Days to achieve complete hematologic remission	26 (18–41)	32 (16–39)	0.4
One-year overall survival	80%	41%	0.02

Figure 1. Comparison of overall survival between patients receiving high-dose hydroxyurea versus no-high-dose hydroxyurea in high-risk APL.

Data availability statement

Data will be made available on reasonable request by contacting the corresponding author.

Written consent was obtained from the patients for treatment and publication.